ClinicalTrials.gg
RecruitingNCT05047133Updated Sep 16, 2021

Effect of Early Administration of TXA in Adult Hip Fractures

A Phase 2/3 interventional study of Tranexamic acid in Postoperative Blood Loss, sponsored by Ascension Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Ascension Health · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2022, 4 years 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage — 5 open to participants now, 5 under way, 1 of them phase 3. Tranexamic Acid · Postoperative Hemorrhage.

Planned enrollment
7th of 25
170 · median 116
Started
2021
with 2 others
Phase 2/3
2 of 25
1 open now
Registered
17th of 25
by date
Lead sponsor
1 of 25
Ascension Health

Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, this one is the 7th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 2/3, and was the 17th registered.

Postoperative Hemorrhage

135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.

Browse Postoperative Hemorrhage studies →

Open to participants now

5 of the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, or all of them as a file.
02

Study summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

03

Conditions studied

  • Postoperative Blood Loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

Exclusion criteria

Exclusion Criteria:

  1. Polytrauma patients
  2. Previous operation on the ipsilateral hip
  3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  4. Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
  5. History of seizure disorder
  6. Patients on
  7. Pregnant Women
  8. Prisoners
  9. Active thromboembolic disease (DVT/PE, MI, Stroke)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Early Adminstration of TXA + Intraoperative TXA

    This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.

    Drug: Tranexamic acid

  • Other
    Intraoperative only TXA

    This group will only receive the intraoperative TXA.

    Drug: Tranexamic acid

Interventions

  • TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups

    Also known as: Lysteda

06

What researchers measure

Primary outcomes

  1. Postoperative Blood Transfusion

    Patient receives a blood transfusion during their postoperative stay in the hospital

    Time frame: Up to two weeks

  2. Overall Blood Loss

    Calculate the difference in postoperative blood loss between groups

    Time frame: Up to two weeks

Secondary outcomes

  1. Length of hospital stay

    Overall length of hospital stay

    Time frame: Up to two weeks

  2. Postoperative Pain

    Difference in overall pain scores between groups

    Time frame: Up to two weeks

  3. Wound complications

    Acute wound complications documented after surgical intervention

    Time frame: Up to two weeks

  4. Acute DVT/PE

    Documented deep venous thrombosis or pulmonary embolism

    Time frame: Up to two weeks

07

Study locations

1 of 1 sites recruiting
  • Ascension Genesys Hospital
    Grand Blanc, Michigan 48439, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Jul 2022, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2021
First posted
Sep 16, 2021
StartActual
Sep 1, 2021
Primary completionEst.
Jul 1, 2022
CompletionEst.
Jul 1, 2022
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05047133
Lead sponsor
Ascension Health
Responsible party
Jacob Hinkley (Resident Physician, Ascension Health) — Principal investigator
First posted
Sep 16, 2021
Start date
Sep 1, 2021
Primary completion
Jul 1, 2022 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
Sep 16, 2021

Study contacts

Jacob Hinkley, DO, MS
Contact
jacob.hinkley2@ascension.org
810-606-5669
Jacob Lytle, DO
Contact
jacob.lytle@ascension.org
810-606-5669

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion